Shreya Lifesciences

About Authors:
Rahul kumar Singh
M.Pharm (Quality Assurance)
Sr. Officer Quality Assurance at Shreya Life Sciences Pvt. Ltd.,
Roorkee, Uttarakhand
rahulsingh.qa@gmail.com

Abstract
Miglitol, an oral alpha-glucosidase inhibitor, is a desoxynojirimycin derivative that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, miglitol reduce levels of glycosylated hemoglobin in patients with Type II (non-insulin-dependent) diabetes mellitus. Systemic nonenzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time. Because its mechanism of action is different, the effect of miglitol to enhance glycemic control is additive to that of sulfonylureas when used in combination. In addition, miglitol diminishes the insulinotropic and weight-increasing effects of sulfonylureas. Miglitol has minor inhibitory activity against lactase and consequently, at the recommended doses, would not be expected to induce lactose intolerance.

Shreya Group has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments. Currently, Shreya operates in Russia, CIS, India, South East Asia and African countries. The Group turnover for the year 2006 was US $ 581 million including US $ 85 million in India.

Shreya Group origins go back to Moscow, Russia, where Shreya Corporation, the parent company, was established in 1995. Once a one-man trading company, Shreya is today the third largest Marketing & Distribution Company in Russia. Shreya Group has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments.

Shreya Group origins go back to Moscow, Russia, where Shreya Corporation, the parent company, was established in 1995. Once a one-man trading company, Shreya is today the third largest Marketing & Distribution Company in Russia. Shreya Group has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments.

Shreya Group origins go back to Moscow, Russia, where Shreya Corporation, the parent company, was established in 1995. Once a one-man trading company, Shreya is today the third largest Marketing & Distribution Company in Russia. Shreya Group has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments.

April 2011

March 2011

Current Vacancies >>>

February 2011

Shreya Group origins go back to Moscow, Russia, where Shreya Corporation, the parent company, was established in 1995. Once a one-man trading company, Shreya is today the third largest Marketing & Distribution Company in Russia. Shreya Group has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments.